<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pioglitazone and metformin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pioglitazone and metformin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pioglitazone and metformin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11431" href="/d/html/11431.html" rel="external">see "Pioglitazone and metformin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709214"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Congestive heart failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones, including pioglitazone, which is a component of pioglitazone/metformin, cause or exacerbate congestive heart failure (CHF) in some patients. After initiation of pioglitazone/metformin and after dose increases, monitor patients carefully for signs and symptoms of heart failure (eg, excessive, rapid weight gain, dyspnea, edema). If heart failure develops, manage the heart failure according to the current standards of care. Furthermore, consider discontinuation or dose reduction of pioglitazone/metformin.</p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone/metformin is not recommended in patients with symptomatic heart failure. Initiation of pioglitazone/metformin in patients with established New York Heart Association (NYHA) class III or IV heart failure is contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate:pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (eg, carbonic anhydrase inhibitors such as topiramate), age 65 years or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (eg, acute heart failure), excessive alcohol intake, and hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information.</p>
<p style="text-indent:-2em;margin-left:2em;">If metformin-associated lactic acidosis is suspected, immediately discontinue pioglitazone/metformin and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F1615054"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Actoplus Met;</li>
<li>Actoplus Met XR [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F1615058"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Biguanide;</li>
<li>
                        Antidiabetic Agent, Thiazolidinedione</li></ul></div>
<div class="block doa drugH1Div" id="F1615087"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> May require a dose reduction of insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia; consider stopping insulin or reducing insulin dose (AACE/ACE [Garber 2020]; ADA/EASD [Davies 2018]; manufacturer’s labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> Use has been associated with an increased risk of heart failure, and risk is increased with concomitant insulin use (AACE/ACE [Garber 2020]; ADA 2021). Avoid use in patients with preexisting heart failure (ADA/EASD [Davies 2018]; Inzucchi 2021). Additional therapeutic considerations may apply; refer to individual agents for information.</p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Pioglitazone 15 mg/metformin 500 mg twice daily <b>or</b> pioglitazone 15 mg/metformin 850 mg tablets once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Inadequately controlled on metformin monotherapy:</i>
<b>Oral: </b>Initial: Pioglitazone 15 mg/metformin 500 mg twice daily or pioglitazone 15 mg/metformin 850 mg once or twice daily (depending on the dose of metformin already being taken).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Inadequately controlled on pioglitazone monotherapy:</i>
<b>Oral: </b>Initial: Pioglitazone 15 mg/metformin 500 twice daily or pioglitazone 15 mg/metformin 850 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment:</b> If necessary, may titrate gradually with careful monitoring of adverse effects (eg, weight gain, edema, signs/symptoms of heart failure). Maximum daily dose: Pioglitazone 45 mg/metformin 2.55 g. Discontinue use if signs or symptoms of heart failure develop (Nesto 2004; manufacturer’s labeling). <b>Note:</b> Metformin daily doses &gt;2 g may be better tolerated if given 3 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">ER tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>Initial: Pioglitazone 15 to 30 mg/metformin 1 g once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Inadequately controlled on metformin or pioglitazone monotherapy:</i>
<b>Oral: </b>Pioglitazone 15 mg/metformin 1 g twice daily or pioglitazone 30 mg/metformin 1 g once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment:</b> If necessary, titrate gradually with careful monitoring of adverse effects (eg, weight gain, edema, signs/symptoms of heart failure). Maximum daily dose: Pioglitazone 45 mg/metformin 2 g. Discontinue use if signs or symptoms of heart failure develop (Nesto 2004; manufacturer’s labeling).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990935"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR &gt;45 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 30 to 45 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preexisting impairment: </i>Use is not recommended for initiation of therapy; refer also to individual agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If eGFR falls between 30 and &lt;45 mL/minute/1.73 m<sup>2</sup> during therapy:</i> Consider benefits/risks of continuing therapy. If continuing therapy, a metformin dosage reduction of 50% (maximum: 1 g/day) and monitoring of renal function every 3 months is recommended (ADA [Lipska 2011]; Inzucchi 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988242"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">IR or ER tablet: The manufacturer recommends avoiding metformin because liver disease is considered a risk factor for the development of lactic acidosis during metformin therapy. However, continued use of metformin in patients with diabetes and chronic liver disease with impaired hepatic function may be associated with a survival benefit in carefully selected patients; use cautiously in patients at risk for lactic acidosis (eg, renal impairment, alcohol use) (Brackett 2010; Crowley 2017; Zhang 2014). Use pioglitazone with caution; therapy interruption or discontinuation may be required if hepatic impairment occurs during therapy. Also see individual agents.</p></div>
<div class="block doe drugH1Div" id="F1615088"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<i>IR or ER tablet:</i> Refer to adult dosing. The initial and maintenance dosing of metformin should be conservative, due to the potential for decreased renal function (monitor).</p></div>
<div class="block adr drugH1Div" id="F1615071"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), diarrhea (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Cardiovascular: Heart failure</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Lactic acidosis, weight gain</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Genitourinary: Bladder carcinoma (FDA Safety Alert, Dec. 19, 2016)</p></div>
<div class="block coi drugH1Div" id="F1615067"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pioglitazone, metformin, or any component of the formulation; established NYHA class III or IV heart failure, severe renal impairment (eg, eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>); metabolic acidosis, including diabetic ketoacidosis.</p></div>
<div class="block war drugH1Div" id="F1615068"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder cancer: An FDA review concluded that although clinical trial data are inconsistent regarding the risk of bladder cancer in patients exposed to pioglitazone, there is still the potential for an increased risk and package labeling has been updated to reflect this. Avoid use of pioglitazone in patients with active bladder cancer and consider risks versus benefits prior to initiating therapy in patients with a history of bladder cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edema: Dose-related edema, including new-onset or exacerbation of existing edema, has been reported with pioglitazone; use with caution in patients with edema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures: An increased incidence of bone fractures in females treated with pioglitazone has been observed; majority of fractures occurred in the lower limb and distal upper limb. Consider risk of fracture prior to initiation and during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Pioglitazone use has been associated with an increased risk of heart failure, and risk is increased with concomitant insulin use (AACE/ACE [Garber 2020]; ADA 2021). Metformin may be used in patients with stable heart failure; use cautiously or avoid in hypoperfusion (ADA 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Pioglitazone may decrease hemoglobin/hematocrit; effects may be related to increased plasma volume.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Hepatic failure, including fatalities, has been reported with pioglitazone.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis: Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue use in patients with conditions associated with dehydration, hypoperfusion, sepsis, or hypoxemia. Temporarily discontinue therapy in patients with restricted food and fluid intake. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Macular edema: Has been reported with thiazolidinedione use, including pioglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. Patients should be seen by an ophthalmologist if any visual symptoms arise during therapy; patients with diabetes should have regular eye exams.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitamin B<sub>12</sub> concentrations: Long-term metformin use is associated with vitamin B<sub>12</sub> deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Weight gain: Dose-related weight gain observed with pioglitazone use; mechanism unknown but likely associated with fluid retention and fat accumulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Use IR tablets after surgery. Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery. ER tablets may have a reduced effect after gastric bypass or sleeve gastrectomy due to the direct bypass of the stomach and proximal small bowel with gastric bypass or a more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Mechanick 2020; Melissas 2013). After gastric bypass (Roux-en-Y gastric bypass [RYGB]), administration of IR tablets led to increased absorption (AUC<sub>0-</sub>
<sub>∞</sub> increased by 21%) and bioavailability (increased by 50%) (Padwal 2011). Lactate levels decrease after gastric bypass (RYGB)-induced weight loss irrespective of the use of metformin. Routinely lowering metformin dose after gastric bypass is not necessary as long as normal renal function is preserved (Deden 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use metformin cautiously in patients at risk for lactic acidosis (Brackett 2010; Crowley 2017; Zhang 2014). In patients with abnormal hepatic tests, pioglitazone therapy should be initiated with caution; therapy interruption or discontinuation may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Metformin is substantially excreted by the kidney; the risk of metformin accumulation and lactic acidosis increases with degree of renal impairment. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; risk of metformin associated lactic acidosis increases with age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ER tablet: Insoluble tablet shell may remain intact and be visible in the stool.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Iodinated contrast: Administration of iodinated contrast agents has been associated with postcontrast acute kidney injury; in patients taking metformin, acute decreases in renal function have been associated with an increased risk of lactic acidosis due to reduced metformin excretion (ACR 2021; manufacturer’s labeling). Refer to metformin monograph for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical procedures: Metformin-containing products should be withheld the day of surgery; restart after renal function is stable (ADA 2021).</p></div>
<div class="block foc drugH1Div" id="F1615096"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, oral: 15/500: Pioglitazone 15 mg and metformin hydrochloride 500 mg; 15/850: Pioglitazone 15 mg and metformin hydrochloride 850 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Actoplus Met:</p>
<p style="text-indent:-2em;margin-left:6em;">15/500: Pioglitazone 15 mg and metformin hydrochloride 500 mg</p>
<p style="text-indent:-2em;margin-left:6em;">15/850: Pioglitazone 15 mg and metformin hydrochloride 850 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, variable release, oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Actoplus Met XR:</p>
<p style="text-indent:-2em;margin-left:6em;">15/1000: Pioglitazone 15 mg [immediate release] and metformin hydrochloride 1000 mg [extended release] [DSC]</p>
<p style="text-indent:-2em;margin-left:6em;">30/1000: Pioglitazone 30 mg [immediate release] and metformin hydrochloride 1000 mg [extended release] [DSC]</p></div>
<div class="block geq drugH1Div" id="F1615056"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes: Excludes variable release tablet</p></div>
<div class="block fee drugH1Div" id="F3422160"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Actoplus Met Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15-850 mg (per each): $11.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pioglitazone HCl-metFORMIN HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15-500 mg (per each): $5.32 - $5.33</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15-850 mg (per each): $5.32 - $5.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F1615092"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with meals. ER tablets should be swallowed whole; do not crush, split, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet formulation is available individually for pioglitazone and metformin. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close monitoring for expected dose reduction or discontinuation requirements is advised in the immediate postoperative period.</p></div>
<div class="block meg drugH1Div" id="F9350997"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Actoplus Met: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F021842s022lbl.pdf%23page%3D41&amp;token=QkvRNAdbIxr20feylFWMVf81X0%2BhPqgX4vdz4APcUBBpSqsTXcnaFhi76K0quh0T1nDpA0HFxeoN3n5lXETRhv54zfFwcdTikb7GGgQnl1bXvFQdozwQ6FhMArgv4s8s&amp;TOPIC_ID=9472" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021842s022lbl.pdf#page=41</a></p>
<p style="text-indent:-2em;margin-left:4em;">Actoplus Met XR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F022024s014lbl.pdf%23page%3D41&amp;token=%2FpOEo3DZ9nLi14UdBcrmNBXYdPuVKu1BbfOWpLKQ5drPqxHmYTVXYLKBUn%2BrfFXiabAaq6x%2FTpOii7w1n%2BIiArMxxDVg7YHU8leETSErWyKycOiksdVQZlCUWtUvMBzQ&amp;TOPIC_ID=9472" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022024s014lbl.pdf#page=41</a></p></div>
<div class="block use drugH1Div" id="F1615060"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p></div>
<div class="block cyt drugH1Div" id="F1615078"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F1615077"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: May enhance the hypoglycemic effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of MetFORMIN. Specifically, excessive alcohol ingestion (acute or chronic) may potentiate the risk of lactic acidosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to cimetidine in patients receiving metformin due to a potential for increased metformin concentrations and toxicity (including lactic acidosis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inducers (Moderate): May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Pioglitazone. Management: Limit the pioglitazone dose to 15 mg daily and monitor for increased pioglitazone toxicities (eg, hypoglycemia) when used in combination with strong CYP2C8 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: May increase the serum concentration of MetFORMIN. Management: Consider alternatives to this combination or use of lower metformin doses. Carefully weigh the risk of metformin toxicities (including lactic acidosis) against the benefit of combining dolutegravir with metformin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with OCT2 substrates when possible. If combined, monitor for increased OCT2 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludeoxyglucose F 18: MetFORMIN may diminish the diagnostic effect of Fludeoxyglucose F 18.  Management: Consider holding metformin for 48 hours or longer prior to PET scans using fludeoxyglucose F18 (FDG-F18) when imaging of the colon or intestine is required. Consider increased monitoring of blood glucose when metformin is held.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guar Gum (Partially Hydrolyzed): May decrease the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Pioglitazone may enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination.  Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MATE1/2-K Inhibitors: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylol Cephalexin: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, and Ritonavir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of MetFORMIN. Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin: May enhance the fluid-retaining effect of Thiazolidinediones.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May increase the serum concentration of MetFORMIN. Management: Limit the metformin dose to a maximum of 1,700 mg per day when used together with ranolazine 1,000 mg twice daily. Monitor patients for metformin toxicities, including lactic acidosis and carefully weigh the risks and benefits of this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Thiazolidinediones may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk for lactic acidosis may be increased. MetFORMIN may increase the serum concentration of Topiramate. Topiramate may increase the serum concentration of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Pioglitazone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: May diminish the therapeutic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): MetFORMIN may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F1615080"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="block rep_considerations drugH1Div" id="F49321392"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Metformin may increase ovulation in premenopausal anovulatory patients resulting in unintended pregnancies.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F1615063"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metformin crosses the placenta (ADA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for information related to the treatment of diabetes mellitus in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F1615066"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Metformin is present in breast milk; excretion of pioglitazone is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block dic drugH1Div" id="F1615091"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy based on the American Diabetes Association recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F1615094"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2021). Monitor renal function (eGFR) prior to therapy initiation and at least annually or at least every 3 to 6 months if eGFR is &lt;60 mL/minute/1.73 m<sup>2</sup> (KDIGO 2020). Monitor hematologic parameters (eg, hemoglobin/hematocrit, red blood cell indices) annually; folate if megaloblastic anemia is suspected; hepatic function (eg, ALT, AST, alkaline phosphatase, total bilirubin) prior to initiation and if signs/symptoms of liver dysfunction occur; signs/symptoms of edema and heart failure; weight gain; signs/symptoms of bladder cancer (eg, dysuria, macroscopic hematuria, dysuria, urinary urgency); ophthalmic exams. Monitor vitamin B<sub>12</sub> serum concentrations every 1 to 2 years, particularly in patients who have been treated with metformin for ≥4 years, or in patients with peripheral neuropathy, anemia, or risk factors for vitamin B<sub>12</sub> deficiency (eg, malabsorption syndromes, reduced dietary intake) (ADA 2021; KDIGO 2020; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2021; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F6117925"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note</b>
<b>: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA1c &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment). In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F1615083"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity.</p>
<p style="text-indent:-2em;margin-left:2em;">Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose, and improves insulin sensitivity (increases peripheral glucose uptake and utilization).</p></div>
<div class="block phk drugH1Div" id="F1615084"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539960"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Actosmet | Glados met</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Piotamax met</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Codiaglit | Glitamin | Metopa | Piobig | Piomin | Politor</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Pizona combi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Actos Met</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone hydrochloride and metformin hydrochloride</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Averofage | Bioglita plus | Diabetonorm plus | Glustacomb | Pioglumet | Piomet | Suganorm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Competact | Glubrava | Pioglitazona/metformina aristo</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone/metformin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Competact | Pioglitazone/metformin genepharm</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Actosmet</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actosmet | Pionix M</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ameto p | Asoformin p | Diamet-Pg | Diavista-m | Exermet p | Formin PL | Formin-p | Glita-m | Glitaris M | Glito m | Glitter-m | Glizone-m | Gluconorm P | Metlong-P | Metpio | Mopaday | P&amp;M | Pio m | Piofix mf | Pioglar m | Pioglar mf | Pioglit-mf | Pioglu-m | Piohope m | Piokap-mf | Piokind m | Piolet-m | Piosafe mf | Piotab m | Piotop ob | Pioz mf | Piozone m | Piozulin m | Pizorad msr | Pye m | Walaphage-pz | Xmet p</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glubrava | Pioglitazone + Metformina EG | Pioglitazone e metformina doc | Pioglitazone e Metformina Mylan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Actosmet</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Metact</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Nilgar m | Pioday m | Piosafe mf</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Actiem met | Actopinmet | Actosmet | Auskomet | Daipro | Diaduo | Glezonemet | Inno.n piomet | K tosmet | Keometfo | Metapio | Metlita | Metpio | Nextosmet | Pazonemet | Pictomin | Pigmet | Pio m | Piobis | Pioformin | Pioglupa | Piolidonmet | Piometa | Piominmet | Piosmet | Piota m | Piotmin | Piotomin | Piromet | Pitaminmet | Unionmet</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Actosmet</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actosmet | Nilgar m | Pioplus | Prialta-Met | Zolid plus</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Diaset plus | Diglyta Plus | Metfor plus | Metpi | Muppet | P met | Pgmin | Pio m | Piobar plus | Piofit Plus | Piomax plus | Pioryl M | Piozone plus | Poze Met</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pioglitazone and metformin | Pioglitazone and Metformin HCl | Pioglitazone and metformin hydrochloride | Pioglitazone hcl and metformin hcl | Pioglitazone hydrochloride and metformin hydrochloride</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Glubrava</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">ActosMet</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Actosmet | Glados met</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Competact</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actosmet</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Acort | Dropia met | Glifix plus | Pio met | Preko</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Actosmet | Lodiglit</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Piosafe mf</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  ActoPlus Met (pioglitazone/metformin) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  ActoPlus Met XR (pioglitazone/metformin) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; December 2017.</div>
</li>
<li>
<div class="reference">
                  Actos (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2013.</div>
</li>
<li>
<div class="reference">
                  American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.3. https://www.acr.org/Clinical-Resources/Contrast-Manual. Published 2021. Accessed July 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference">
                  American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20452916">
<a name="20452916"></a>Brackett CC. Clarifying metformin’s role and risks in liver dysfunction. <i>J Am Pharm Assoc (2003)</i>. 2010;50(3):407-410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/20452916/pubmed" id="20452916" target="_blank">20452916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28055049">
<a name="28055049"></a>Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. <i>Ann Intern Med.</i> 2017;166(3):191-200. doi: 10.7326/M16-1901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/28055049/pubmed" id="28055049" target="_blank">28055049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29058235">
<a name="29058235"></a>Deden LN, Aarts EO, Aelfers SCW, et al. Risk of metformin-associated lactic acidosis (MALA) in patients after gastric bypass surgery. <i>Obes Surg</i>. 2018;28(4):1080-1085. doi: 10.1007/s11695-017-2974-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/29058235/pubmed" id="29058235" target="_blank">29058235</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  FDA Safety Alert. MedWatch. Pioglitazone-containing medicines: drug safety communication – updated FDA review, increased risk of bladder cancer. Food and Drug Administration website. Available at <a href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery" target="_blank">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm532772.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>. Accessed December 19, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract.</i> 2020;26(1):107-139. doi:10.4158/CS-2019-0472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Inzucchi SE. Thiazolidinediones in the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25536258">
<a name="25536258"></a>Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <i>JAMA</i>. 2014;312(24):2668-2675. doi: 10.1001/jama.2014.15298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/25536258/pubmed" id="25536258" target="_blank">25536258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(suppl 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi: 10.1210/jc.2019-00198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21617112">
<a name="21617112"></a>Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. <i>Diabetes Care</i>. 2011;34(6):1431-1437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/21617112/pubmed" id="21617112" target="_blank">21617112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi: 10.1097/SLA.0b013e3182774522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693998">
<a name="14693998"></a>Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. <i>Diabetes Care</i>. 2004;27(1):256-263. doi:10.2337/diacare.27.1.256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/14693998/pubmed" id="14693998" target="_blank">14693998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21478461">
<a name="21478461"></a>Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. <i>Diabetes Care</i>. 2011;34(6):1295-1300. doi: 10.2337/dc10-2140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/21478461/pubmed" id="21478461" target="_blank">21478461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24798175">
<a name="24798175"></a>Zhang X, Harmsen WS, Mettler TA, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. <i>Hepatology</i>. 2014;60(6):2008-2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pioglitazone-and-metformin-drug-information/abstract-text/24798175/pubmed" id="24798175" target="_blank">24798175</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9472 Version 253.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
